Compare NTLA & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | AVAH |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2016 | 2021 |
| Metric | NTLA | AVAH |
|---|---|---|
| Price | $12.33 | $6.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 9 |
| Target Price | ★ $20.02 | $9.75 |
| AVG Volume (30 Days) | ★ 4.4M | 1.0M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.43 | ★ 1850.00 |
| EPS | N/A | ★ 1.05 |
| Revenue | $67,671,000.00 | ★ $2,433,199,000.00 |
| Revenue This Year | N/A | $7.31 |
| Revenue Next Year | $62.75 | $5.59 |
| P/E Ratio | ★ N/A | $6.32 |
| Revenue Growth | 16.92 | ★ 20.19 |
| 52 Week Low | $6.83 | $3.73 |
| 52 Week High | $28.24 | $10.32 |
| Indicator | NTLA | AVAH |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 45.13 |
| Support Level | $11.19 | $6.11 |
| Resistance Level | $14.71 | $6.93 |
| Average True Range (ATR) | 1.18 | 0.28 |
| MACD | -0.27 | 0.03 |
| Stochastic Oscillator | 11.03 | 45.06 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.